A Phase 2, Multi-Cohort, Open-Label, Multicenter Study to Determine the Efficacy and Safety of BB2121 in Subjects with Multiple Myeloma (KarMMa-2)
A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of Oprozomib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Myeloma-Developing Regimens Using Genomics (MyDRUG) (Genomics guided multi-arm trial of targeted agents alone or in combination with a backbone regimen) MASTER PROTOCOL
A Phase 1/2 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects with Relapsed or Refractory Multiple Myeloma
A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma Version Number: 1.3 Version Date: 09/24/2014
A Phase I in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects with Relapsed or Refractory Multiple Myeloma
Phase I Multicenter, Open Label, Dose-Escalation Study To Determine The Maximum Tolerated Dose For Trichostatin A In Subjects With Relapsed Or Refractory Hematologic Malignancies
Phase 1 / 2 trial of Idasanutlin in combination with Ixazomib and dexamethasone in patients with 17p deleted, relapsed multiple myeloma
A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma
An Open-Label Phase 1/2 Study of JCARH125, BCMA targeted Chimeric Antigen Receptor (CAR) T Cells, in Subjects with Relapsed or Refractory Multiple Myeloma
![Alert Sign](https://www.hackensackumc.org/wp-content/themes/hackensack-umc/images/exclamation-triangle.svg")
![Close Alert Box](https://www.hackensackumc.org/wp-content/themes/hackensack-umc/images/X.svg")
